What are the challenges in selecting pharmacotherapy for pregnant women with inflammatory bowel disease?

Recenti Prog Med. 2021 May;112(5):371-377. doi: 10.1701/3608.35874.

Abstract

The peak of incidence of inflammatory bowel disease (IBD) overlaps with the peak of reproductive age. Moreover, women affected by IBD are often concerned with the possible negative effects of their disease and medications on pregnancy and birth outcomes. From a physician point of view, managing IBD in pregnancy is challenging. Disease activity is the major cause of poor pregnancy outcomes and, therefore, achieving and maintaining IBD remission for the whole duration of pregnancy is the main therapeutic goal. The challenges in selecting therapy lie in balancing the proven efficacy of each drug with the level of safety uncertainty. Except for methotrexate and thalidomide, for which it exits an absolute contraindication in pregnancy, the evidence actually available suggest that most medications can be safely used during pregnancy if appropriately prescribed. The risks associated with drug withdrawal may be higher than the known risks of the medications themselves on pregnancy outcomes. However, all the decisions should be shared with the patient, all available information should be discussed and any therapeutic strategy must be tailored according to patient's context, including disease pattern, activity, severity and acceptance of risk.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chronic Disease
  • Female
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Methotrexate / adverse effects
  • Pregnancy
  • Pregnancy Complications* / drug therapy
  • Pregnancy Outcome
  • Pregnant Women

Substances

  • Methotrexate